DME Capital Management LP Has $10.33 Million Holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

DME Capital Management LP boosted its position in Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) by 44.2% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 468,550 shares of the company's stock after purchasing an additional 143,700 shares during the period. Teva Pharmaceutical Industries makes up about 0.5% of DME Capital Management LP's portfolio, making the stock its 22nd largest holding. DME Capital Management LP's holdings in Teva Pharmaceutical Industries were worth $10,327,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in the company. Barclays PLC lifted its holdings in shares of Teva Pharmaceutical Industries by 31.7% during the third quarter. Barclays PLC now owns 427,595 shares of the company's stock valued at $7,705,000 after purchasing an additional 102,848 shares during the last quarter. Wilmington Savings Fund Society FSB purchased a new stake in shares of Teva Pharmaceutical Industries in the 3rd quarter valued at approximately $50,000. Franklin Resources Inc. grew its position in Teva Pharmaceutical Industries by 141.7% during the 3rd quarter. Franklin Resources Inc. now owns 155,091 shares of the company's stock worth $2,674,000 after purchasing an additional 90,920 shares in the last quarter. GAMMA Investing LLC grew its position in Teva Pharmaceutical Industries by 44.5% during the 4th quarter. GAMMA Investing LLC now owns 7,458 shares of the company's stock worth $164,000 after purchasing an additional 2,297 shares in the last quarter. Finally, First Hawaiian Bank purchased a new position in Teva Pharmaceutical Industries during the 4th quarter worth approximately $723,000. 54.05% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on TEVA shares. Hsbc Global Res upgraded shares of Teva Pharmaceutical Industries to a "strong-buy" rating in a research report on Monday, April 28th. Piper Sandler increased their price target on shares of Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the stock an "overweight" rating in a research report on Friday, January 17th. Barclays reduced their price target on shares of Teva Pharmaceutical Industries from $28.00 to $26.00 and set an "overweight" rating for the company in a research report on Thursday, January 30th. UBS Group reduced their price target on shares of Teva Pharmaceutical Industries from $30.00 to $27.00 and set a "buy" rating for the company in a research report on Thursday, January 30th. Finally, Bank of America increased their price target on shares of Teva Pharmaceutical Industries from $20.00 to $22.00 and gave the stock a "buy" rating in a research report on Thursday, May 8th. Eight analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, Teva Pharmaceutical Industries presently has a consensus rating of "Buy" and an average target price of $24.43.

Teva Pharmaceutical Industries Price Performance

Shares of Teva Pharmaceutical Industries stock traded down $0.58 during mid-day trading on Tuesday, reaching $17.38. 7,751,439 shares of the stock were exchanged, compared to its average volume of 10,058,699. The company has a market cap of $19.71 billion, a price-to-earnings ratio of -11.99, a price-to-earnings-growth ratio of 1.44 and a beta of 0.62. The firm has a 50-day simple moving average of $15.22 and a 200 day simple moving average of $17.44. The company has a current ratio of 0.98, a quick ratio of 0.75 and a debt-to-equity ratio of 2.97. Teva Pharmaceutical Industries Limited has a fifty-two week low of $12.47 and a fifty-two week high of $22.80.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last released its earnings results on Wednesday, May 7th. The company reported $0.52 EPS for the quarter, beating the consensus estimate of $0.47 by $0.05. Teva Pharmaceutical Industries had a positive return on equity of 42.46% and a negative net margin of 9.91%. The company had revenue of $3.89 billion during the quarter, compared to analysts' expectations of $3.99 billion. During the same period last year, the firm earned $0.48 EPS. The business's revenue for the quarter was up 1.9% on a year-over-year basis. On average, sell-side analysts predict that Teva Pharmaceutical Industries Limited will post 2.5 EPS for the current fiscal year.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.